VGVadim V. Gusev

Vadim V. Gusev

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Vadim V. Gusev has a total of 43 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Challenges in the Differential Diagnosis of Transitory Ischemic Attack and Migraine with Aura in 14-Year-Old Adolescent: Case Study

    by Lolita O. Nasyrova, Mariya D. Skurikhina, Anna V. Gorodnicheva, Olga A. L’Vova, Vadim V. Gusev, Alexey S. Shamkin, Polina E. Pukis, Marina E. Zenger, Л. О. Насырова, М. Д. Cкурихина, et al.

    Background. Transitory ischemic attacks (TIA) remain a significant public health problem in the pediatric population. The difficulties of diagnostics of TIA in children and the high risk of recurrence (up to 40%) are due to the lack of standards for the patients management, as well as the similarity of the clinical manifestations of TIA with other paroxysmal states (migraine with aura, for example). Case description . A 14-year-old girl was admitted to the hospital in the home area, complaints: headaches, blurred vision (a “light line” in the left F.V.), numb feeling of the left hand, lasts up to 2.5 hours. Diagnosis: migraine with aura. At the checkup the carrier state of variants of six genes (FGB, F13, ITGA2, PAI-1, MTR, MTRR) associated with thrombophilia was revealed, as well as hypoplasia of the right vertebral artery, Kimmerle anomaly with extravasal compression, atrial septal defect, and bradycardia. Recurrent TIAs were diagnosed in the vertebrobasilar territory. Acidum acetylsalicylicum (75 mg/day) was prescribed as per the off-label, with complete relief of TIA episodes for 2 years. Withdrawal of the drug provoked a recurrence of TIA. The resumption of Antiplatelet therapy ensured the onset of remission. Conclusion. Diagnostics of TIA in children is a complex clinical case which requires to exclude a wide range of diseases (migraine with aura, epilepsy, demyelinating diseases). To diagnose the TIA promptly doctors need to remain alert to cerebrovascular pathology, they also need an interdisciplinary step-by-step approach, and analyze the risk factors (thrombophilic gene variants, vascular anomalies, and cardiac pathology). When prescribing antiplatelet therapy to children with TIA doctors conduct the laboratory efficacy monitoring (ASPI test), when discontinuing the therapy doctors assess the risk/benefit ratio due to high risk of relapse.

  • Treatment of chronic nonspecific low back pain in spinal osteoarthritis: effectiveness of Ambene Bio combined with standard therapeutic approach

    by M.A. Bakhtadze, O.S. Davydov, A.E. Barulin, V.V. Gusev, F.I. Devlikamova, O.B. Doronina, P.P. Kalinsky, Yu.V. Karakulova, O.V. Kurushina, D.I. Lebedeva, et al.

    Objective. To evaluate the effect of treatment with Ambene Bio on chronic nonspecific LBP and spinal OA in patients with and without central sensitivity syndrome (CSS). Material and methods. The sample consisted of 120 patients with chronic nonspecific LBP and spinal OA with and without CSS. Results. Regardless of clinically significant CSS, reduction of LBP and functional activity after combined treatment with Ambene Bio showed significant improvements compared to standard treatment. Satisfaction with treatment was significantly higher after combined therapy. Conclusion. Treatment of chronic nonspecific lower back pain and spinal osteoarthritis has a clinical advantage when standard therapy is combined with Ambene Bio, as it significantly reduces pain, improves functional activity and contributes to higher satisfaction with treatment.

  • Surgical correction of resistant cervical dystonia: evolution of methods and current trends (a systematic review)

    by E. A. Chizhova, V. V. Gusev, A. B. Bogomolova

    Cervical dystonia (CD) is the most common form of focal dystonia, characterized by abnormal head posture, chronic pain, and significant reduction in quality of life. Botulinum toxin therapy is the first — line standard, but 10–30 % of patients develop resistance or insufficient response, necessitating effective surgical alternatives. Objective — to analyze the evolution, efficacy, and safety of all known surgical methods for cervical dystonia to optimize clinical decision — making. Material and methods. A systematic literature analysis was performed using PubMed, Scopus, eLibrary, and Cochrane Library databases covering the period 1960–2026. Results. Three main surgical eras were identified: destructive (thalamotomy, pallidotomy), peripheral denervation (Bertrand’s operation with modifications), and neuromodulation — deep brain stimulation (DBS). A network meta — analysis of 55 studies (2032 patients) demonstrates superiority of DBS in the degree of improvement (mean difference 7.03–10.71 points on the TWSTRS scale) and safety profile compared to selective peripheral denervation (SPD). Conclusion. Deep brain stimulation of the globus pallidus internus (GPi) or subthalamic nucleus (STN) is the current gold standard for resistant forms of CD. SPD remains relevant as a less expensive and technically accessible alternative in resource — limited settings.

  • Influence of central sensitivity syndrome on symptoms of chronic nonspecific low back pain in patients with spinal osteoarthritis

    by M.A. Bakhtadze, O.S. Davydov, A.E. Barulin, V.V. Gusev, F.I. Devlikamova, O.B. Doronina, P.P. Kalinsky, Yu.V. Karakulova, V.V. Kim, O.V. Kurushina, et al.

    Objective. To evaluate the influence of central sensitivity syndrome (CSS) on symptoms of chronic nonspecific low back pain (LBP) in patients with spinal osteoarthritis. Material and methods. Patients with chronic nonspecific LBP (n=120) and spinal osteoarthritis (OA) were divided into two equal groups (n=60). The 1st group included patients with clinically insignificant CSS (CSI score <35). The 2nd group included patients with clinically significant CSS (CSI score ≥35). Both groups were compared regarding duration of disease and exacerbation; LBP intensity; degree of disability; risk of LBP chronicity; number of descriptors of various painful sensations and associated affective reactions. Results. Both groups were comparable regarding anthropometric parameters; duration of disease and exacerbation; back and leg pain intensity. The following parameters (median) were lower in the 1st group: total CSI score (22 vs 47 points); disability according to the Roland-Morris Disability Questionnaire (10 vs 13.5 points); risk of chronicity according to the Keele STarT Back Tool (4 vs 7 points); SF-MPQ-2 total score (41 vs 67 points). Patients in the 2nd group often complained on symptoms typical for chronic fatigue syndrome, fibromyalgia, and clinical depression. Conclusion. Central sensitivity syndrome limits daily activities of patients with chronic low back pain and exacerbates its course. Patients with chronic low back pain and clinically significant central sensitivity syndrome predominantly demonstrate symptoms typical for chronic fatigue syndrome, fibromyalgia, and depression. In such cases, low back pain may be one of the symptoms of these conditions.

  • Open Access

    Cognitive Impairments and the Possibility of Their Correction in Patients with Muscular Dystonia

    by Вадим Венальевич Гусев, Анастасия Борисовна Богомолова

    Introduction. Modern scientific literature frequently reports impairments in cognitive abilities in patients with muscle dystonia. However, there is still no consensus regarding their pharmacological correction. To find a potential solution to this problem, the authors of this study evaluated the effect of botulinum therapy on cognitive changes in patients with muscle dystonia. The aim of the study was to assess cognitive abilities in patients with muscle dystonia before and after botulinum therapy. Materials and methods. The study involved 28 patients of both sexes diagnosed with muscle dystonia, who received two injections of botulinum toxin at a 4-month interval. A comparative analysis was conducted of the muscle dystonia severity scores on the TWSTRS scale and cognitive abilities on the MoCA scale, obtained before and after botulinum therapy. Statistical data processing was performed using an application software package with standard algorithms of variation statistics. The Student’s t-test was used for comparing variables. Differences were considered statistically significant at p < 0.010. Results and discussion. The study revealed a statistically significant positive effect of botulinum therapy on both assessed parameters: the severity of muscle dystonia decreased by an average of nearly 30.0 %, and the patients’ cognitive abilities improved by an average of 14.5 %. The obtained data suggest a direct link between motor and cognitive functions. Thus, the use of botulinum toxin drugs in the therapy of muscle dystonia with concomitant cognitive impairments may be clinically justified and promising. Conclusions. The potential for using botulinum toxin not only as a muscle relaxant but also for the targeted correction of cognitive impairments in patients with muscle dystonia has been identified. These results open new prospects for the comprehensive rehabilitation of such patients and require further investigation within the framework of long-term follow-up observation.

  • Open Access

    Review of Transient Amnestic Syndromes: Focus on Transient Global Amnesia

    by Yana A. Shukshina, Вадим Венальевич Гусев

    Introduction. Transient amnestic syndrome (TAS) is a short-term memory disorder characterized by a temporary reduction in the ability to memorize and recall information. Diagnosis of this condition can be challenging due to the nonspecific clinical presentation and the variety of etiologic factors. Objective is to use literature data to identify methods and features of differential diagnosis for conditions associated with TAS, determine the clinical manifestations and additional examination data in patients with transient global amnesia (TGA), the most common manifestation of TAS, and establish the causes, precipitating factors, and risk factors for the development of TGA. Materials and methods. A search and analysis of global literature was conducted using the following platforms: eLibrary.ru, Google Scholar, PubMed, and CyberLeninka. Results. This paper summarizes literature data on the history of the emergence and introduction into clinical practice of the concept of TGA, which is the most common manifestation of TGA, its clinical manifestations, theories regarding the causes and mechanisms of TGA development, and methods of differential diagnosis and prognosis. Conclusions. TAS is a very common clinical syndrome observed in various diseases and secondary brain dysfunction. TGA is one of the most common causes and manifestations of TAS. TGA is an acutely emerging neurological syndrome, the key manifestation of which is sudden, transient memory dysfunction. It is characterized by the combined development of anterograde and retrograde amnesia, with the episode duration typically not exceeding 24 hours. An important diagnostic criterion is the absence of other focal neurological symptoms. Despite the clear clinical picture, the etiology and pathogenesis of TGA remain a subject of scientific debate, and the available data are highly contradictory. Despite its benign nature, TGA remains a challenging diagnostic task in neurology. Its diagnosis requires the exclusion of serious neurological pathologies that present with a similar TAS. Differential diagnosis includes cerebrovascular diseases (transient ischemic attack, stroke), acute hypertensive encephalopathy, epileptic and psychogenic amnesia.

  • The effectiveness of using a centrally acting muscle relaxant in combination with botulinum toxin injections in patients with spasmodic torticollis

    by V.V. Gusev, E.A. Makarov, O.A. Lvova, A.B. Bogomolova

    Objective. To analyze the efficacy of eperison in combination with botulinum toxin injections for the treatment of pain syndrome in patients with spastic torticollis (ST). Material and methods. A retrospective study was conducted to evaluate the effectiveness of eperison administration alongside botulinum therapy in 29 patients diagnosed with ST. The study employed a cross-sectional retrospective analysis of medical data. Patients receiving botulinum toxin injections at three-month intervals (a total of 6 cycles), with assessments at 2 months (4—6 cycles after each injection), were administered eperison at a dose of 150 mg/day. The efficacy of the treatments was evaluated using a validated scale: the 85-point TWSTRS (Toronto Western Spasmodic Torticollis Rating Scale), assessed three times—before each botulinum injection (on day 1), at day 14, and and at day 60 later. Results. For cycles 1—3 (botulinum toxin, without eperisone), the average TWSTRS scale score on the on day 1 of each cycle was 40.72 — 41.66; cycles 4—6 with the addition of Eperisone — 26.6—30.4 points. When comparing the average values of the TWSTRS scale for cycles 1—3 and cycles 4—6 on the «Pain» scale, t-test value was: 15.85 (p=0.000546). Conclusion. The intake of the centrally acting muscle relaxant eperison resulted in a statistically significant improvement in patients with ST by the time of the next injection (paired Student’s t-test 2.77—2.92, p=0.05), including improvements in the «Pain» scale, compared to botulinum therapy without eperison in the same patients.

  • Experience of long-term use of botulinum toxin type A-hemagglutinin complex in the rehabilitation of patients who have suffered ischemic stroke resulting in focal spasticity: interim results

    by V. V. Gusev, D. A. Medvedeva

    Focal post-stroke spasticity significantly impairs the functioning and quality of life of patients. Therapy with botulinum toxin type A – hemagglutinin complex is an effective method of stabilizing the level of post-stroke spasticity, reduces the severity of restrictions on self-care and work activity of patients. Purpose of the study: to evaluate the effectiveness of long-term use of botulinum toxin therapy in the rehabilitation of patients with focal post- stroke spasticity.Materials and methods. The study included clinical data of 24 patients who had suffered a stroke and were receiving treatment within the third stage of rehabilitation. Two groups of patients were identified: the main group (n=12) received treatment with the botulinum toxin type A hemagglutinin complex (the drug «Dysport®») for 12 years (a total of 30–45 courses of injection treatment per patient over 12 years of observation) and symptomatic treatment of focal spasticity, physical rehabilitation courses (therapeutic exercise classes, medical massage, physiotherapy), and the control group (n=12) received physical rehabilitation courses. The research method was a one-time retrospective analysis of medical data, followed by an annual assessment of the degree of limitations in life activities, motor function impairment, dynamics of the level of focal spasticity, and severity of pain syndrome during 12 years of observation. Results. Over 12 years of observation of patients in both groups, there was a significant improvement in the quality of life, a decrease in motor disorders, and a decrease in pain in patients in the main group.Conclusions. Therapy of focal post-stroke spasticity with botulinum toxin type A – hemagglutinin complex (the drug «Dysport»®) is effective as a therapy for reducing pain syndrome, improving the quality of life and self-care of patients in the long term.

  • Open Access

    Use of botulinum toxin in patients with dysphagia and sialorrhea in acute ischemic stroke

    by V. V. Gusev, T. V. Balueva, O. V. Zayceva, D. A. Smirnov

    Dysphagia and sialorrhea are common complications of stroke that worsen quality of life and increase the risk of aspiration pneumonia. Botulinum toxin type A (BoNT-A) injections are effective in the treatment of sialorrhea, but there are few data on the use of botulinum toxin in patients with dysphagia in acute stroke. Objective: to evaluate the efficacy and safety of incobotulinumtoxin A in the treatment of sialorrhea and prevention of aspiration pneumonia in patients with acute ischemic stroke. Material and methods. Twenty-seven patients with dysphagia and sialorrhea in acute ischemic stroke were included in the study. All patients received an ultrasound-guided injection of incobotulinumtoxin A in a total dose of 100 units, divided into four injections into parotid and submandibular salivary glands bilaterally. Posterior sialorrhea was visually verified by the endoscopic assessment, severity of dysphagia and aspiration risk were assessed at baseline, two weeks and one month post-injection using the Penetration Aspiration Scale (PAS), Fiberoptic Endoscopic Dysphagia Severity Scale (FEDSS) and the Clinical Institute of the Brain (CIB) Dysphagia Scale. The control group consisted of 27 retrospectively analyzed patients who were matched for age, gender, stroke severity and dysphagia. Sialorrhea was assessed endoscopically, and dysphagia was assessed using the CIB dysphagia scale. All patients were routinely treated according to local standards of care depending on their condition at the admission. Aspiration complications and adverse events due to incobotulinumtoxin A were recorded throughout the study. Results. All patients in the main group at baseline had severe dysphagia according to PAS, FEDSS and CIB dysphagia scales (5.88±1.37; 4.73±1.12 and 19.81±6.61 points, respectively) and sialorrhea. After 2 weeks and 1 month after the injection of incobotulinumtoxin A, there was a decrease in the amount of saliva without signs of posterior sialorrhea and a decrease in the severity of dysphagia. Dysphagia scores on the PAS, FEDSS and CIB scales reached a statistically significant difference (pConclusion. Injections of incobotulinumtoxin A in patients with dysphagia in acute ischemic stroke are effective and safe in the treatment of sialorrhea and the prevention of aspiration pneumonia. BoNT-A injections could be considered as a routine, safe and cost-effective treatment for patients with dysphagia to prevent aspiration complications after stroke. Further studies are needed to substantiate this statement.


  • Comparative analysis of the effectiveness of Botulinum toxin type A — hemagglutinin preparations of the Relatox and Botox complex in the treatment of patients with primary idiopathic blepharospasm

    by V.V. Gusev, E.A. Makarov, O.A. Lvova

    Objective. To analyze the effectiveness of Relatox (Botulinum toxin type A — hemagglutinin complex) in comparison with Botox in the treatment of primary idiopathic blepharospasm. Material and methods. The study included clinical data for 21 patients with blepharospasm who were treated by botulinum therapy with Botox and Relatox for 3 years. The research method is a one-step retrospective analysis of medical data. Injections were carried out with a 3-month interval. On the 6th cycle, the drug was switched to Relatox. The clinical efficacy of the drugs was assessed using an 8-point Jankovich evaluation scale: the average values before the injection and 14 days after it were compared for each procedure. Results. Mean Jankovich scale scores decreased 2.5-fold for all cycles by the second week after the procedure (4.95 pre-injection vs. 1.8 post-injection), and the mean paired Student’s T-criterion for all injections was 7.14 (with a critical value of 2.021 and a significance level of p=0.05). The mean paired Student’s T-criterion for Botox was –6.63 and for Relatox –7.5 (with a critical value of 2.021 and a significance level of p=0.05), indicating a high efficacy of both drugs, slightly higher for Relatox. Conclusion. A consistent trend of increasing efficacy with regular botulinum toxin injections and greater efficacy of Relatox compared to Botox in the treatment of patients with primary idiopathic blepharospasm has been demonstrated.